Low molecular weight heparins for the prevention of venous thromboembolisms in patients with kidney failure;Niedermolekulare heparine zur prophylaxe venöser thromboembolien bei patienten mit niereninsuffizienz

Vasomed

Volumn 23, Issue 3, 2011, Pages 118-122

  Bauersachs, Rupert ^a   Bramlage, Peter ^b  

^a KLINIKUM DARMSTADT   (Germany)

^b Institut für Kardiovaskuläre Pharmakologie und Epidemiologie   (Germany)

Author keywords

Bleeding risk; Creatinine clearance; Molecular weight

Indexed keywords

LOW MOLECULAR WEIGHT HEPARIN;

ARTICLE; DISEASE SEVERITY; HUMAN; KIDNEY FAILURE; TREATMENT INDICATION;

EID: 79960282638     PISSN: 09421181     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. AWMF, S3-Guideline: Prophylaxis of venous thromboembolism (VTE). http://www.awmf.org/uploads/tx-szleitlinien/003-001-S3-AWMF-Leitlinie- Prophylaxe-der-venoesen-Thromboembolie-VTE-Lang-04-2009-12-2013.pdf 2010.
2. th edition). Chest 2008;133:381S-453S.
3. Bauersachs R, Schellong SM, Haas S et al. CERTIFY: Prophylaxis of venous thromboembolism in patients with severe renal insufficiency. Thromb Haemost 2011;105(6):981-989.
4. Frydman A, Low-molecular-weight heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humans. Haemostasis 1996; 26 Suppl 2:24-38. (Pubitemid 26099958)
5. Hoffmann U, Harenberg J, Bauer K et al. Bioequivalence of subcutaneous and intravenous body-weight-independent high-dose low-molecular-weight heparin Certoparin on anti-Xa, Heptest, and tissue factor pathway inhibitor activity in volunteers. Blood Coagul Fibrinolysis 2002;13:289-296.
6. Cadroy Y, Pourrat J, Baladre MF et al. Delayed elimination of enoxaparin in patients with chronic renal insufficiency. Thromb Res 1991;63:385-390.
7. Schmid P, Brodmann D, Odermatt Y et al. Study of bioaccumulation of dalteparin at a therapeutic dose in patients with renal insufficiency. J Thromb Haemost 2009;7:1629-1632.
8. Siguret V, Pautas E, Fevrier M et al. Elderly patients treated with tinzaparin (Innohep) administered once daily (175 anti-Xa IU/kg): anti-Xa and anti-IIa activities over 10 days. Thromb Haemost 2000;84:800-804.
9. Mismetti P, Laporte-Simitsidis S, Navarro C et al. Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin). Thromb Haemost 1998;79:1162-1165. (Pubitemid 28297165)
10. Pautas E, Gouin I, Bellot O et al. Safety profile of tinzaparin administered once daily at a standard curative dose in two hundred very elderly patients. Drug Saf 2002;25:725-733. (Pubitemid 34983375)
11. Sanderink GJ, Guimart CG, Ozoux ML et al. Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment. Thromb Res 2002;105:225-231. (Pubitemid 34260945)
12. Schmid P, Brodmann D, Fischer AG et al. Prospective observational cohort study of bioaccumulation of dalteparin at a prophylactic dose in patients with peritoneal dialysis. J Thromb Haemost 2010;8:850-852.
13. Douketis J, Cook D, Meade M et al. Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study. Arch Intern Med 2008;168:1805-1812.
14. Rahn A. Certoparin for thrombosis prophylaxis in geriatric patients: accumulation in connection with age-associated reduction of renal function. Euro J Ger 2008;10:28-32.
15. Mahe I, Aghassarian M, Drouet L et al. Tinzaparin and enoxaparin given at prophylactic dose for eight days in medical elderly patients with impaired renal function: a comparative pharmacokinetic study. Thromb Haemost 2007;97:581-586.